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Abstract Nonsense-mediated decay is well known by the
lucid definition of being a RNA surveillance mechanism
that ensures the speedy degradation of mRNAs containing
premature translation termination codons. However, as we
review here, NMD is far from being a simple quality
control mechanism; it also regulates the stability of many
wild-type transcripts. We summarise the abundance of
research that has characterised each of the NMD factors
and present a unified model for the recognition of NMD
substrates. The contentious issue of how and where NMD
occurs is also discussed, particularly with regard to
P-bodies and SMG6-driven endonucleolytic degradation. In
recent years, the discovery of additional functions played
by several of the NMD factors has further complicated the
picture. Therefore, we also review the reported roles of
UPF1, SMG1 and SMG6 in other cellular processes.
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Introduction
The cascade of events during gene expression, from
transcription of the DNA encoded genetic information to
the eventual protein synthesis, arguably represents some
of the most influential biochemical pathways for a living
organism. Naturally, diverse regulation mechanisms have
evolved to ensure the accuracy of gene expression at
multiple levels, amongst them is a process commonly
referred to as nonsense-mediated mRNA decay (NMD)
or mRNA surveillance. Thirty years ago, it was obs-
erved in Saccharomyces cerevisiae that nonsense codons
truncating the open reading frame (ORF) of the ura3
mRNA dramatically reduced the RNA’s half-life [1] and
that in b0-thalassemic patients homozygous for a non-
sense mutation in the b-globin gene, the b-globin
mRNA was subjected to rapid degradation [2]. Fast
degradation of mRNAs harbouring truncated ORFs due
to premature translation termination codons (PTCs) was
subsequently documented in many other organisms, and
it is believed to occur in most if not all eukaryotes
(reviewed in [3]). The names coined to describe this
PTC-associated mRNA turnover pathway, NMD and
mRNA surveillance, emphasise its quality control func-
tion in preventing the production of potentially
deleterious C-terminally truncated proteins translated
from PTC-containing mRNAs. However, it has become
clear during recent years that many physiological
mRNAs are also NMD substrates, indicating a role for
NMD beyond mRNA quality control as a translation-
dependent post-transcriptional regulator of gene expres-
sion (reviewed in [4]).
Herein, we describe different types of NMD substrates
and review recent literature that has led to a unified
molecular model for the identification of NMD eliciting
mRNAs. Additionally, we summarise our knowledge
about the trans-acting NMD factors, their biochemical
features and the intriguing double-life of several of these
factors.
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NMD targets both aberrant and physiological
transcripts
One important group of NMD substrates comprise tran-
scripts harbouring a PTC that truncates their ORFs. If not
detected and degraded, the PTC-containing (PTC?)
transcripts can result in the accumulation of potentially
harmful C-terminally truncated proteins. PTC? transcripts
arise either by mutations (or rearrangements in the case of
immunoglobulin genes) at the DNA level, or at the RNA
level due to errors in transcription, pre-mRNA processing
and in particular by aberrant alternative splicing
(Table 1).
On the DNA level, direct nonsense mutations and more
frequently frame-shifting deletions and insertions generate
PTCs. Moreover, mutations at splice sites or splicing
regulatory sequences can result in aberrantly spliced
PTC? transcripts. The programmed DNA rearrangements
occurring in the immunoglobulin and T-cell receptor
genes during lymphocyte maturation generate PTCs at a
high frequency, due to random deletions and the addition
of non-templated nucleotides at the recombination sites
(reviewed in [5]). Hence, NMD is very important for the
differentiation and maintenance of hematopoietic cells
[6].
Errors during transcription can also produce PTC?
transcripts, albeit less frequently. In contrast, unproductive
alternative splicing is believed to constitute a major source
of PTC? mRNAs in mammals. As much as 95% of multi-
exon human genes are alternatively spliced [7], and the
average number of alternatively spliced mRNA isoforms
per gene is approximately 3.5 in humans [8]. Using bio-
informatics approaches, it was proposed that about one-
third of the alternatively spliced human mRNAs contain a
PTC, implying a widespread coupling of alternative
splicing and NMD [9]. For example, several studies have
revealed that some alternative splicing (AS) events exploit
NMD for post-transcriptional regulation (termed regulated
unproductive splicing and translation: RUST or AS-NMD
[9]). This type of regulation is common for many splicing
regulators, including SR proteins and hnRNPs, which
indicates an important feedback regulation of splicing
(reviewed in [10, 11]). Interestingly, such PTC-introducing
exons often coincide with ultra-conserved genomic ele-
ments, suggesting a key role for RUST in vertebrate
biology. However, a microarray profiling study determin-
ing the relative levels of PTC? compared to the PTC-free
splice variants in a variety of mammalian tissue types
proposed that most PTC-generating alternative splicing
events located within the ORF of mammalian genes pro-
duce PTC? mRNAs that are not under strong positive
selection pressure and hence are unlikely to have important
functional roles [12]. Altogether, this advocates that cells
produce a large number of faulty PTC? mRNAs that are
recognised and eliminated by NMD. Nonetheless, several
studies have inferred an even broader role of the NMD
pathway in muting the ‘‘transcriptional noise’’ of suppos-
edly non-functional RNAs such as transcribed
pseudogenes, ancient transposons or mRNA-like non-pro-
tein coding RNAs from intergenic regions [13–15].
Another group of NMD substrates includes physiologi-
cal RNA transcripts that encode functional full-length
proteins. A crucial role of NMD, not only as a vacuum
cleaner for aberrant transcripts but also as a regulator of
physiological mRNA abundance, became apparent due to
several microarray studies in different organisms (reviewed
in [16]). Transcriptome-profiling with NMD-deficient
Saccharomyces cerevisiae, Drosophila melanogaster and
Homo sapiens cells revealed that NMD directly and indi-
rectly controls the abundance of 3–10% of all mRNAs in
the respective cells [14, 17–21]. Several features of phys-
iological mRNAs can render them NMD-sensitive,
whereas some mRNAs have evolved stabilising elements
protecting them from NMD. Notably, introns in the 30
untranslated regions (30 UTR), ORFs located upstream of
the main coding region (uORFs), programmed frameshifts
and long 30 UTRs all can elicit NMD. Messenger RNAs
containing UGA triplet(s) that direct selenocysteine
incorporation represent an interesting case of NMD sub-
strates; when selenium is abundant, UGA codes for
Table 1 Transcripts that can be targeted for NMD in mammalian
cells
PTC? PTCs arising at
DNA level
Nonsense mutations that
directly generate PTCs
Nucleotide insertions and
deletions that shift the
reading frame
Mutations leading to splice
signal alterations
DNA rearrangements of
immunoglobulin and T-cell
receptor genes
PTCs arising at
RNA level
Transcription errors
Faulty or alternative splicing
Pre-mRNAs that escaped
nuclear retention
Programmed frameshifts
PTC- Physiological
mRNAs
mRNAs with uORF
mRNAs with introns
in the 30 UTR
mRNAs with long 30 UTRs
Selenoprotein mRNAs
mRNAs of transposons,
retroviruses and
pseudogenes
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selenocysteine, but it is interpreted as a PTC when the
selenium concentration is low [22] (see ‘‘In selenium-
deprived cells, NMD reduces the selenoprotein encoding
mRNA’’ for a discussion of selenoproteins and NMD). The
large and diverse repertoire of transcripts controlled by
NMD reflects the significant influence of NMD on the
metabolism of the cell and consequently in many human
diseases.
NMD is implicated in the modulation of many genetic
diseases
There are numerous examples of human diseases associ-
ated with mutations that result in PTCs [23–25]. If
translated, the PTC? mRNAs would give rise to truncated
proteins that have either completely lost their function, are
still functional, have acquired dominant-negative function
or have gained new functions. As a consequence of these
different possibilities, NMD has a double-edged effect on
the manifestation of a disease: NMD is detrimental if it
prevents the production of proteins with some residual
function, but it is beneficial if it prevents the synthesis of
toxic truncated proteins. Hence, NMD represents a crucial
modulator of the clinical outcome of many genetic
diseases.
The majority of PTC? disease-associated alleles exert
their negative effects due to insufficient production of a
functional protein. An example where NMD aggravates the
clinical outcome is provided by several disease phenotypes
caused by mutations in the dystrophin gene. While most of
the truncating mutations in the dystrophin gene are asso-
ciated with a similar phenotype, the rare truncating
mutations that occur near the 30 end of the dystrophin gene
can result in extremely variable phenotypes. It has been
suggested that all truncated proteins encoded by genes with
mutations near the 30 end would in theory be capable of
rescuing the DMD phenotype, but when NMD prevents
their synthesis, the clinical manifestations of the disease
are aggravated [26]. Conversely, NMD has a well-docu-
mented beneficial role in the degradation of PTC?
b-globin mRNA, thereby preventing the synthesis of
C-terminally truncated b-globin that would otherwise
cause toxic precipitation together with surplus a-globin
chains. In a heterozygote context, the second wild-type
allele supports almost normal levels of b-globin synthesis,
contributing to the correct haemoglobin assembly, which is
reflected in the recessive inheritance of this b-thalassemia
type. However, rare NMD-insensitive PTCs are responsible
for the dominant form of b-thalassemia [27, 28].
Given the general inspection and clean-up role of NMD,
it is not surprising that diseases associated with pre-
mature translation termination are remarkably diverse.
Furthermore, as alluded to above, the PTC position deter-
mines if NMD ensues and this contributes to the severity of
the clinical manifestations. To list a few examples of this
diversity: (1) the disease severity in the connective tissue
disorder Marfan syndrome correlates with the abundance of
the PTC? fibrillin 1 (FBN1) mRNA [29], (2) PTCs at
different positions in CFTR (cystic fibrosis transmem-
brane-conductance regulator) can cause mild to severe
cystic fibrosis [30], and (3) truncated forms of IFNGR1
(interferon gamma receptor 1) can result in recessively or
dominantly inherited susceptibility to mycobacterial
infections [31, 32].
NMD also appears to play a prominent role in carcino-
genesis. PTCs in several tumour suppressor genes
(BRCA1, p53, WT1) have been reported to result in
reduced abundance of their mRNAs due to NMD [33–36].
Indeed, a strategy referred to as ‘‘gene identification by
NMD inhibition’’ (GINI) has been successfully used to
identify tumour suppressor genes [37, 38], pointing to a
crucial role of NMD in eliminating faulty tumour sup-
pressor transcripts and thus protecting cells from malignant
growth.
In addition to diseases that result from nonsense muta-
tions, defects in NMD factors can also cause disease. A
recent study identified mutations in the NMD core factor
UPF3B to be responsible for X-linked mental retardation
[39]. Furthermore, there is a growing body of evidence that
many physiological transcripts are subject to NMD regu-
lation. It is likely that the impairment of NMD-dependent
regulation of the abundance of these mRNAs is a yet to be
identified cause of various human diseases.
For many disorders caused by PTC-generating muta-
tions there are no effective treatments yet available.
However, in instances where NMD eliminates transcripts
that, despite the PTC, would still encode a functional
protein, promising results have been obtained with PTC
read-through approaches. Remarkably, as little as 1–5% of
normal protein levels can greatly reduce or eliminate the
principal manifestations of PTC-associated diseases such
as cystic fibrosis and Hurler syndrome [40–42]. Amino-
glycoside antibiotics (e.g. gentamicin) have been shown in
vitro to suppress nonsense mutations by promoting read-
through of termination codons and have improved CFTR
function in clinical trials with cystic fibrosis patients [43,
44]. However, very high aminoglycoside concentrations
are required and the associated toxic side effects have
limited their clinical use. Instead, a new suppressor of
PTCs was recently reported that selectively induces ribo-
somal read-through only at PTCs and not at natural
termination codons [45]. This small molecular compound,
called Ataluren (formerly PTC124), rescued striated mus-
cle function in mdx mice (a model for muscular dystrophy)
and has been tested in phase II clinical trials on cystic
NMD in human cells 679
fibrosis patients. The oral administration of the drug
reduced the epithelial electrophysiological abnormalities
caused by CFTR dysfunction. Ataluren was generally well
tolerated with infrequent and mild to moderate adverse
effects [46]. These results are encouraging and the appli-
cation of Ataluren might well be extended to other diseases
such as DMD.
The parts list: human NMD factors
The first trans-acting factors required for NMD were
identified through genetic screens in S. cerevisiae (called
Upfs, for up-frameshift; [47–50]) and in C. elegans (called
SMGs, for suppressor of morphological defects on geni-
talia; [51–53]). The human orthologues were later
identified based on sequence similarities [54–61]. The
NMD pathway in human cells comprises the factors UPF1,
UPF2, UPF3A, UPF3B, SMG1, SMG5, SMG6 and SMG7,
with UPF1, UPF2 and UPF3 (A and B) being the homo-
logues of C. elegans SMG2, SMG3 and SMG4,
respectively (reviewed in [3]; Table 2). More recently, four
additional NMD factors have been described: NAG,
DHX34, SMG8 and SMG9. RNAi-mediated depletion of
NAG and DHX34, the human homologues of C. elegans
SMGL-1 and SMGL-2, increased the abundance of a NMD
reporter mRNA [62]. The two factors SMG8 and SMG9
were shown to regulate SMG1 kinase activity in human
cells and their knockdowns moderately stabilised a
PTC? b-globin reporter transcript [63]. An interspecies
comparison of NMD factors revealed a number of inter-
esting differences with probable mechanistic consequences
(see below). While SMG7 is present in mammals and
C. elegans, D. melanogaster appears to lack a SMG7 homo-
logue [64], and in contrast to metazoans, S. cerevisiae only
requires UPF1, UPF2 and UPF3 for NMD. SMG5 and
SMG6 homologues are not present in S. cerevisiae and
deletion of the SMG7 homologue Ebs1p has been shown to
only slightly increase the abundance of endogenous NMD
targets [65].
The UPF proteins constitute the core NMD machinery
Of all the UPF genes, UPF1 is functionally the most
important factor for NMD and hence is the most conserved
[3, 66]. UPF1 is a group 1 RNA helicase and nucleic acid-
dependent ATPase. The ATPase activity resides in two of
the seven helicase motifs in the middle section of the
protein and is linked to the 50-to-30 helicase activity [67,
68]. ATP hydrolysis provides the energy to facilitate
modulations in the structure of RNA or RNA–protein
complexes [69]. UPF1 interacts with UPF2 [56, 60, 70]
through its N-terminal cysteine- and histidine-rich (CH)
domain, which displays a unique combination of three
zinc-binding motifs arranged in two tandem modules [71].
UPF1 also interacts with the eukaryotic translation release
factors eRF1 and eRF3 [72, 73], and Kashima et al.
reported based on immunoprecipitation experiments that
UPF1 forms a complex with SMG1, eRF1 and eRF3
(called SURF complex [74]). UPF1 is a phosphoprotein
and sequential phosphorylation/dephosphorylation cycles
are essential for NMD in mammals and C. elegans because
they contribute to remodelling of the mRNA surveillance
complex [58]. The C-terminal serine-glutamine (SQ)
motifs of UPF1 are targets for phosphorylation by SMG1
[55, 61, 75]. In addition to the SMG1 kinase, UPF1
phosphorylation was shown to require UPF2 and UPF3 [66,
74, 75], but more recent studies have provided evidence for
both UPF2-independent and UPF3-independent NMD
pathways [73, 76–79]. The phosphorylation of UPF1
probably induces the dissociation of eRF3 from UPF1,
since it was found that the over-expression of a SMG1
mutant deficient for its kinase activity strongly increased
UPF1 co-immunoprecipitation with eRF3 [74]. Phosphor-
ylated UPF1 interacts with SMG5, SMG6 and SMG7,
which in turn promotes dephosphorylation of UPF1 by the
protein phosphatase PP2A [58, 80, 81].
Similar to UPF1, UPF2 is also a phosphoprotein, both in
mammals [81] and in S. cerevisiae [82]. Phosphorylation of
the yeast Upf2p occurs at serine residues in its N-terminal
domain. Together with other specific amino acids in the
N-terminal region, these serine residues are responsible for
eliciting NMD and for the interaction of Upf2p with Hrp1p,
an RNA-binding protein implicated in yeast NMD [82].
The N-terminal region also contains several nuclear
localisation signals (NLS), yet the protein resides pre-
dominantly in the cytoplasm [56, 57, 60]. Besides binding
to UPF1, UPF2 also interacts through a separate surface
with UPF3, thereby acting as a bridge between these two
proteins [56, 60, 83, 84]. The two regions of human UPF2
that contact UPF1 have been mapped to amino acids 94–
133 and 1,085–1,124/1,167–1,194, with the C-terminal
region of UPF2 contributing more to the interaction [60].
The precise interaction of the C-terminal region of UPF2
with the CH domain of UPF1 has recently been determined
in a structural study [70]. Using highly conserved, mainly
negatively-charged, residues in the last of its three MIF4G
(middle portion of eIF4G) domains, UPF2 interacts with a
mainly positively-charged b-sheet surface of the RNP
domain (ribonucleoprotein-type RNA-binding domain) of
UPF3B [85]. Notably, UPF2 alone and the UPF2-UPF3B
complex, but not UPF3B alone, bind to RNA in vitro [85].
UPF3 is the least conserved of the UPF proteins [3]. In
contrast to yeast, nematodes and flies, the human genome
encodes two UPF3 genes: UPF3A on chromosome 13 and
UPF3B (also called UPF3X) on the X chromosome [56,
680 P. Nicholson et al.
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60]. Both genes generate two alternatively spliced mRNAs,
resulting in four UPF3 isoforms. In UPF3B, skipping of
exon 8 leads to a protein lacking amino acids 270–282 of
the otherwise 483 amino acids containing polypeptide, and
exon 4 skipping of UPF3A results in a 420 amino acids
containing UPF3AS protein, lacking amino acids 117–149
of the 452 amino acids long UPF3AL isoform [60]. Two
proteins corresponding in mass to UPF3AS and UPF3AL
have been detected using an UPF3A-specific anti-serum
[86], but the short form is probably not ubiquitously pro-
duced [87]. UPF3A and UPF3B share an overall similarity
of 60%, with the N-terminal amino acids 38–236 (com-
prising the RNP domain and a nuclear export signal) being
the most conserved (86% similarity). The C-terminal
halves (amino acids 202–453) are considerably more
divergent and harbour one or several NLSs [56, 60].
Despite the extensive similarity, tethering assays have
shown that UPF3B is more effective than UPF3A at trig-
gering NMD and stimulating translation [88]. High activity
in NMD correlates with a short C-terminal sequence motif
that is well conserved in UPF3B of different species, but
not in UPF3A proteins [88]. Recently, it was shown that
UPF3A and UPF3B compete for binding to UPF2 and
consequently, when UPF3B levels are low, more UPF3A
can bind to UPF2, which stabilises UPF3A because UPF3A
alone is likely to be inherently unstable. On the other hand,
when UPF3B levels are high, less UPF3A can bind to
UPF2 and therefore the UPF3A levels decrease. Most
likely it is crucial that UPF3A is quickly degraded when
UPF3B levels are high because UPF3A is a less efficient
NMD activator [87]. The UPF3 proteins are components of
the exon-junction complex (EJC) [89]. The C-terminal
region of UPF3 interacts with a composite binding site of
the EJC core [90, 91] comprising parts of Y14, MAGOH
and eIF4A3 [88, 92, 93].
The SMG proteins determine the phosphorylation status
of UPF1
As previously mentioned, SMG1 is a protein kinase that
can phosphorylate UPF1 [55, 61]. SMG1 belongs to the
phosphatidylinositol 3-kinase-related protein kinase
(PIKK) super family and functions specifically as a serine-
threonine kinase (reviewed in [94]). Regulation of UPF1’s
phosphorylation state during NMD is probably limited to
metazoans because S. cerevisiae appear to lack orthologues
of SMG1, SMG5 and SMG6, and NMD is only moderately
affected by a deletion of the SMG7 homologue Ebs1p [65].
Biochemical studies have revealed SMG1 in different
multi-protein complexes: in addition to the SURF complex,
where SMG1 is associated with UPF1, eRF1 and eRF3,
SMG1 also co-immunoprecipitates with EJC components
(eIF4A3, Y14, MAGOH) and NMD factors (UPF1, UPF2,T
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UPF3A, UPF3B and SMG7) in HeLa cell extracts [74].
There is evidence that UPF1 phosphorylation requires the
association between the SURF complex and the EJC, and
that this association is mediated by direct interactions of
SMG1 with UPF2 and/or Y14 [74].
C. elegans mutated for SMG5, SMG6 or SMG7 are
deficient in NMD and accumulate hyper-phosphorylated
SMG2 (the UPF1 orthologue), suggesting that these factors
are required for dephosphorylation of SMG2 [66]. More-
over, SMG5 interacts specifically with phosphorylated
SMG2, with SMG7, and with the structural and catalytic
subunits of protein phosphatase 2A (PP2A), inferring that
SMG5 may give PP2A specificity for UPF1 [80]. Similarly,
human SMG6 was also shown to co-purify with the cata-
lytic subunit of PP2A, SMG1, UPF1, UPF2 and UPF3B,
and also to specifically target dephosphorylation of UPF1,
but not of UPF2 [81]. (Please note that SMG6 is termed
Smg5/7a in this study.)
SMG5, SMG6 and SMG7 share a similar domain
organisation: all contain two tetratricopeptide (TPR)
repeats, either at the N-terminus (SMG5 and SMG7) or in
the middle section (SMG6). TPR-containing domains
consist of 34 amino acids long TPR repeats that usually
function as mediators of protein–protein interactions [95].
For SMG7, the TPRs were shown to adopt a similar fold to
14-3-3, which is a signal-transduction protein that binds
phosphoserine-containing polypeptides. Sequence similar-
ities suggest conservation of this 14-3-3-like domain
structure in SMG5 and SMG6 [96], and in SMG7 this
domain is responsible for binding to UPF1 [96] as well
as contributing to an interaction with the corresponding
14-3-3-like domain of SMG5 [97].
SMG5 and SMG6 contain a PIN-like domain (for PilT N
terminus) in their C-termini. Generally, PIN-like domains
function as phosphodiesterases and often exhibit nuclease
activity [98]. Despite the fact that the PIN-like domains of
SMG5 and SMG6 adopt a similar overall fold that is
related to ribonucleases of the RNase H family, SMG6
harbours the canonical triad of acidic residues crucial for
RNase H activity, whereas SMG5 lacks two of these three
key catalytic residues [99]. These structural differences are
reflected at the molecular level, as only the PIN domain of
SMG6 has nuclease activity on single-stranded RNA in
vitro [99], and it was recently demonstrated in human and
Drosophila cells that SMG6 is the endonuclease that
can initiate cleavage of nonsense mRNA near the PTC
[100, 101] (see below).
Intracellular localization of NMD factors
Reliable determination of the intracellular distribution of
any protein by immunofluorescence microscopy depends
on the availability of highly specific antibodies. Moreover,
plasmid-based expression of tagged proteins or GFP fusion
proteins can produce non-physiological localisation pat-
terns. With this caveat in mind, immunolocalisation studies
of NMD factors in human cells revealed that UPF1 local-
ises predominantly to the cytoplasm [56, 60]. However,
biochemical evidence implies that UPF1 shuttles between
the cytoplasm and the nucleus [102], which is consistent
with its role in both nuclear and cytoplasmic processes
([103, 104] and see below). UPF2 exhibits perinuclear
cytoplasmic localisation and UPF3 is a nucleo-cytoplasmic
shuttling protein with steady-state nuclear localisation [56,
60]. The SMG5, SMG6 and SMG7 proteins are all local-
ised to the cytoplasm. Over-expressed SMG5 and SMG7,
together with UPF1, co-localise with P-bodies, and the
C-terminus of SMG7 has been shown to be required for
this localisation [96, 97, 105]. In contrast, it was shown
that over-expressed SMG6 accumulated in separate cyto-
plasmic foci [97]. Biochemical fractionation and immuno-
fluorescence microscopy revealed that SMG1 localises to
both the cytoplasm and the nucleus [106].
Intriguingly, in Arabidopsis thaliana, most of UPF3 and
a substantial fraction of UPF2 were recently reported to
localise to the nucleolus, and nucleolar fractions were
highly enriched in aberrant mRNAs that are NMD sub-
strates [107].
Distinguishing between proper and aberrant translation
termination
NMD strictly depends on reading frame recognition and
therefore on translation. The decision of whether NMD is
to be initiated or not is made when a ribosome stalls at any
of the three termination codons (UAG, UGA and UAA).
The local mRNP environment of the termination codon
influences the process of translation termination (reviewed
in [108–110]). During normal translation termination,
eRF1 recognises the termination codon in the A-site of the
stalling ribosome and forms a complex with the GTPase
eRF3 to catalyse peptide release [111–113]. Through its
C-terminal region eRF3 interacts with the C-terminus of
eRF1, while the N-terminal region of eRF3 interacts with
the C-terminal domain of poly(A)-binding protein (PABP)
[114–116], which is believed to stimulate proper and effi-
cient translation termination [117] (Fig. 1). It has been
shown in yeast that when the interaction between the eRF3
orthologue Sup35 and Pab1p is impaired, the terminating
ribosome cannot efficiently dissociate from the mRNA
[118]. Consistent with the corresponding role of mamma-
lian cytoplasmic poly(A) binding protein 1 (PABPC1) in
stimulating translation termination, it was recently dem-
onstrated that mammalian cells lacking PABPC1 exhibited
increased read-through of termination codons [73]. In the
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case of transcripts that are subjected to NMD, the inter-
action between eRF3 and PABPC1 is less efficient and is
antagonised by UPF1 recruitment [119] (Fig. 2). In S. cere-
visiae, D. melanogaster and human cells, NMD can be
suppressed by tethering PABP near the PTC [73, 118–122],
which further supports the NMD antagonising function of
PABP.
The key NMD factor UPF1 has been shown to interact
with eRF3 and eRF1 [72], but it is currently unknown how
UPF1 is recruited to the terminating ribosome, and if it is
present in all termination events. There is evidence that the
decision of whether NMD is to be triggered or not relies
upon competition between UPF1 and PABP for binding to
eRF3 on the terminating ribosome [119]. The outcome of
this competition is largely influenced by the structure of the
mRNP [121]. Extensive research using a variety of model
systems has provided a multitude of data regarding the
NMD-triggering characteristics of mRNPs. One clearly
defined NMD-eliciting feature is the length of the 30 UTR,
which proposes that the physical distance between the
termination codon and the poly(A) tail of the transcript
determines the fate of the mRNA. Experiments carried out
in yeast, worms, plants, human and fly cell lines revealed
that termination codons are recognised by the NMD
machinery when they are situated too far upstream from the
poly(A) tail [52, 62, 118–121, 123–126]. The ‘‘faux 30
UTR model’’ was first coined to describe NMD in yeast,
proposing that premature termination is intrinsically
abnormal since the long 30 UTR is not properly configured
to bring Pab1p into the proximity of termination codon to
ensure efficient translation termination [118]. Based on the
aforementioned studies conducted in a variety of organ-
isms, we advocate extension of the ‘‘faux 30 UTR model’’
to a unified model that explains the basic mechanism for
recognition of NMD substrates in all organisms [4]
(Fig. 2). In the situation of the NMD-inhibiting signal from
PABP being absent, then UPF2 and/or UPF3 can bind to
UPF1. In mammals, UPF1 is present in the SURF complex
and UPF2 and/or UPF3B are thought to promote SMG1-
mediated phosphorylation of UPF1 [74]. Subsequently,
SMG5, SMG6 and/or SMG7 proteins can bind to phos-
phorylated UPF1, eventually leading to the degradation of
the transcript. The results from Kashima et al. argue that
phosphorylation of UPF1 requires both UPF2 and UPF3B
[74]. Yet, recent data from other laboratories unveiled the
existence of both UPF2-independent and UPF3-indepen-
dent branches of the NMD pathway [73, 76–79].
Numerous investigations have shown that not only the
physical distance of the 30 UTR but also the specific RNA
sequences that it contains can determine the fate of the
mRNA. For example, it was proposed that the surveillance
complex scans and identifies a downstream sequence ele-
ment (DSE) that stimulates NMD in yeast, but this element
has remained poorly defined [127, 128]. Despite the fact
that similar sequence elements have not been found in
mammals, it is possible that a longer 30 UTR provides a
better platform for binding of trans-acting factors that
improve NMD efficiency. The average 30 UTR length in
humans is 700–800 nucleotides, yet experiments with
reporter mRNAs harbouring 30 UTRs that are only 200–300
nucleotides in length were already able to display some
destabilisation due to NMD in human cell culture [121]. As
proposed by Singh et al., mRNAs containing long 30 UTRs
have perhaps evolved mechanisms to evade NMD [119].
The stability can possibly be achieved by highly structured
30 UTRs, where RNA base pairing and internal loops can
bring the poly(A) tail closer to the termination codon [121].
Furthermore, specific RNA sequences or secondary struc-
tures might recruit NMD antagonising factors to the
vicinity of the stop codon.
Fig. 1 Schematic model of efficient translation termination in the
proper mRNP environment. The model postulates that normal
translation termination involves an interaction between PABP and
eRF3, which by a currently unknown mechanism promotes fast
polypeptide release, disassembly of the ribosomal subunits and re-
initiation of the ribosome at the start codon. The proper termination-
stimulating mRNP environment is characterised by a protein complex
involving PABP, eIF4G, the cap binding factor (eIF4E or CBP80/
CBP20) and additional factors that bring the 50 and the 30 ends of the
mRNA in close proximity and constrain the mRNP in a circular
structure
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Mammalian tissue culture studies have established the
splicing-dependent EJC [129, 130] as another important
trans-acting component for NMD initiation. The mamma-
lian transcriptome is complex with a large number of multi-
exon genes and extensive alternative splicing. One-third of
all alternatively spliced transcripts are expected to be NMD
substrates [9]. The coupling of a splicing-dependent signal
to NMD facilitates efficient recognition of this group of
NMD substrates and increases the accuracy of gene
expression [131–133]. Indeed, if a termination codon
occurs prematurely in the mRNA, it is probable that an
exon–exon junction will be present downstream of the
Fig. 2 Model for aberrant translation termination, which leads to the
assembly of a mRNA surveillance complex that marks the mRNA for
subsequent degradation. When the stop codon is located in an mRNP
environment where it fails to receive the PABP-mediated termination-
stimulating signal, the ribosome stalls for a prolonged period of time
at the stop codon, which allows binding of UPF1 to eRF3. The
assembly of this SURF complex marks the mRNA for NMD. The
model further postulates that this marking step is still reversible and
that the mRNA is only irreversibly committed to NMD after UPF1
phosphorylation (licensing step). UPF2 and/or UPF3 are necessary for
SMG1-mediated UPF1 phosphorylation. The presence of an EJC in
the 30 UTR serves as a strong enhancer of NMD (EJC-enhanced
licensing), because UPF2 and/or UPF3 interaction with the SURF is
greatly facilitated by virtue of their close proximity, whereas UPF2
and/or UPF3 recruitment take longer in the absence of an EJC (EJC-
independent licensing), resulting in overall less efficient NMD.
Following phosphorylation and possibly induced by ATP hydrolysis,
UPF1 undergoes a conformational change that increases its affinity
for RNA and is then ready for interaction with SMG5–7, which
initiate mRNA degradation (see Fig. 3)
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PTC, and this probability increases the further upstream the
PTC is located. During pre-mRNA splicing, EJCs are
deposited 20–24 nucleotides upstream of exon–exon
junctions [129]. The EJC is a dynamic structure with a
heterogeneous protein composition, wherein the proteins
Y14, MAGOH, eIF4A3 and Barentsz (Btz) remain asso-
ciated with mRNA after export into the cytoplasm and
constitute the stable core of the EJC [90, 91]. The NMD
factors UPF2 and UPF3 have been found associated with
EJC, which hinted for a role of the EJC in NMD [89]. It is
thought that EJCs located within an ORF are removed by
elongating ribosomes in a process that involves the ribo-
some-associated protein PYM [134]. In contrast, EJCs
located downstream of the termination codon remain
associated with the mRNP. The presence of an EJC
downstream of the SURF complex greatly facilitates UPF2
and/or UPF3 interacting with the SURF by virtue of their
close proximity. According to this mechanistic model, the
presence of an EJC downstream of the termination codon
serves as a potent enhancer of NMD (Fig. 2; reviewed in
[110]).
Another interesting observation with regards to NMD
efficiency as a function of PTC position is that in several
mRNAs PTCs close to the translation initiation codon fail
to elicit efficient NMD [36, 121, 135–138]. It is known that
PABPC1 can bind to eukaryotic initiation factor 4G
(eIF4G) which acts to bridge the 30 and 50 ends of the
mRNA into a circular structure that enhances translation
[139, 140]. In this closed-loop structure, the NMD sup-
pressor PABPC1 would also be in close distance to the 50
region of an mRNA where it can antagonise NMD initia-
tion at early PTCs, regardless of the presence of
downstream EJCs [122, 141]. In addition, the ribosome
could initiate at an in-frame AUG downstream of the early
PTC and so remove the remaining EJCs from the mRNA,
which would eliminate a potent promoter of NMD.
In mammalian cells, NMD has been proposed to occur
during the so-called pioneer round of translation, before
eIF4E replaces the cap-binding complex (CBC) [142].
CBP80, which is a constituent of the CBC, has been shown
to interact with UPF1 and the knockdown of CBP80
reversed NMD, but not the repression of steady-state
translation through the translation inhibitor 4E-BP1 ([143,
144], reviewed in [10]). In contrast, NMD occurs mainly
on eIF4E-bound mRNAs in S. cerevisiae: CBC-bound
transcripts are largely insensitive to NMD and the yeast
homologue of CBP80 is dispensable for NMD [145–147].
In summary, we believe that most of the currently
available experimental data support a NMD model in
which the competitive interaction between UPF1 and
PABP with the ribosome-bound release factors is the key
determinant for NMD initiation. Alternative models that
remain to be experimentally tested were recently proposed
by Brogna and Wen [148]. It is not yet possible to unam-
biguously predict which mRNPs are able to elicit NMD
and to explain each of the discussed NMD-triggering fea-
tures of mRNPs. A variety of studies have shown that
certain cis-acting elements, such as long 30 UTRs or the
presence of EJCs downstream of the termination codon, are
sufficient on their own to trigger NMD, probably because,
in both cases, UPF1 binding to eRF3 and subsequently to
UPF2 and/or UPF3 is facilitated. Nonetheless, neither a
long 30 UTR, a downstream EJC nor any other reported
NMD triggering feature on mRNA is absolutely required
for NMD. Therefore, the only certain requirement for
NMD so far is the translation-dependent recruitment of
UPF1 to the mRNA.
Degradation of NMD targets
Evidence for endonucleolytic and exonucleolytic decay
pathways
Messenger RNA turnover involves an important and
tightly regulated set of ribonuclease-mediated degradation
pathways used by eukaryotic cells to regulate normal gene
expression, to get rid of aberrant mRNAs (e.g. those
containing PTCs) and to eliminate parasitic mRNA spe-
cies (viral mRNAs, transposons). Due to their critical
functions, many of the ribonucleases responsible for RNA
degradation are highly conserved amongst eukaryotes
[149–152]. Degradation of normal mRNAs is generally
initiated by the removal of the poly(A) tail from the 30
end of mRNAs. In yeast, the deadenylation reaction is
catalysed by the Ccr4p/Caf1p complex, while in mam-
mals the poly(A) tail is shortened by the consecutive
action of two different complexes: the PAN2/PAN3
complex first shortens full-length poly(A) tails of
approximately 200 bases to approximately 110 bases.
These intermediate poly(A) tails are subsequently targeted
by the CCR4/CAF1 complex that removes the remaining
adenines [153] and followed by exonucleolytic degrada-
tion of the transcript in 30-to-50 direction by the exosome
[154]. Concomitant with CCR4/CAF1-mediated dead-
enylation, the decapping enzyme DCP1/DCP2 removes
the 7-methyl guanosine (m7G) cap structure, leaving an
unprotected 50 end that is accessible for rapid degradation
by the abundant 50-to-30 exonuclease XRN1.
An important question to address is what pathway of
degradation NMD follows. For instance, are the general
mRNA turnover pathways utilised after improper transla-
tion termination, or is NMD initiated by special nucleases?
In S. cerevisiae, degradation of PTC? mRNAs has been
shown to rely on the general mRNA turnover pathway and
a modification thereof that is typified by deadenylation-
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independent removal of the m7G-cap structure, followed by
subsequent Xrn1p-mediated 50-to-30 exonucleolytic decay
[155, 156]. However, NMD substrates were also found to
be channelled into a degradation pathway that involves
deadenylation followed by 30-to-50 exonucleolysis by the
exosome and Ski complexes [155, 157]. In contrast, NMD
in D. melanogaster is elicited by endonucleolytic cleavage
of the PTC? mRNA in the vicinity of the PTC. The
resulting 50 and 30 decay intermediates are then rapidly
degraded in the 30-to-50 direction by the exosome and in the
50-to-30 direction by XRN1, respectively, and can only be
detected in cells depleted for the aforementioned exonuc-
leases [158]. In human cells, the situation is less clear and
probably more complex. Degradation of NMD reporter
transcripts via the conventional mRNA turnover pathway,
starting with deadenylation, followed by decapping and
XRN1-mediated exonucleolytic decay, has been reported
[159–161] (Fig. 3; SMG5/SMG7 mediated exonucleoly-
sis). Consistent with a role of decapping in human NMD,
UPF1 and DCP1a have recently been documented to
interact via a protein called PNRC2 [162]. On the other
hand, endonucleolytic cleavage near the PTC has recently
been demonstrated in human cells depleted for XRN1
[100]. Moreover, the PIN domain of SMG6 was shown to
possess the endonuclease activity responsible for initiating
NMD in both Drosophila and human cells [100, 101].
Therefore, it seems that mammalian NMD targets can be
degraded by both a SMG6-dependent endonucleolytic
pathway and a deadenylation- and decapping-dependent
exonucleolytic pathway (Fig. 3; SMG6 mediated
Fig. 3 Model for degradation
of NMD substrates. The model
posits that UPF1-bound mRNAs
can be degraded by two
different pathways, depending
on whether the SMG5/SMG7
heterodimer or the endonuclease
SMG6 binds to phosphorylated
UPF1. Interaction of SMG5/
SMG7 with phospho-UPF1
promotes deadenylation
followed by decapping and
exonucleolytic RNA decay from
both ends (left branch).
Interaction of SMG6 with
phospho-UPF1 leads to a
SMG6-mediated
endonucleolytic cleavage near
the aberrant termination site,
followed by the exonucleolytic
degradation of the two RNA
fragments from the initial
cleavage site
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endocleavage), whereas Drosophila NMD is confined to
the former and yeast NMD to the latter decay pathway.
Consistent with this conclusion, mammals possess both
SMG6 and SMG7, whereas Drosophila lacks a SMG7
homologue and yeast has no SMG6 equivalent. Further
work is required to determine the relative contributions of
the two decay pathways involved in mammalian NMD and
to understand what determines which decay route is taken
by the different types of mRNAs directed to the NMD
pathway.
Does human NMD take place in P-bodies?
Prominent cytoplasmic foci called processing bodies
(P-bodies, also called DCP1- or GW-bodies) have
received ample attention during the last few years because
they seem to represent important sites for translational
repression and mRNA decay [163–165]. These highly
dynamic granules are enriched for components of the
decapping and 50-to-30 degradation machinery, including
DCP1/DCP2, the decapping activators RCK/p54, Hedls/
Ge-1, EDC3 and Pat1, the Lsm1-7 complex and the 50-to-
30 exonuclease XRN1. Mammalian P-bodies also contain
the deadenylases CCR4/CAF1 and PAN2/PAN3 [166], as
well as components of the miRNA pathway [164].
Additionally, it has been found that, under certain con-
ditions, the NMD factors UPF1, UPF2, UPF3, SMG5 and
SMG7 are localised in P-bodies [97, 105, 162, 167]. The
co-localisation of the mRNA degradation machinery and
of various NMD factors in P-bodies has stimulated
research on the functional significance of P-bodies in
NMD. In yeast cells, Upf1p, Upf2p and Upf3p accumu-
late in P-bodies in Ddcp1, Ddcp2 or Dxrn1 strains [167].
Furthermore, a NMD reporter transcript was shown to
localise to P-bodies in an Upf1p-dependent manner and
more NMD reporter transcript accumulated in P-bodies of
Dupf2 or Dupf3 strains [167]. These observations argue
that NMD in yeast occurs within complexes that can
accumulate into P-bodies. In contrast, NMD was not
affected in Drosophila and human cells by RNAi-medi-
ated depletion of GW182 and Ge-1, a treatment that
prevented the formation of any microscopically visible
P-bodies [168, 169]. These results indicate that NMD
does not require the presence of P-bodies in metazoans.
Moreover, SMG6 does not co-localise with P-bodies [97],
which is consistent with the view that most NMD in
human cells might occur outside of P-bodies where it is
initiated by a decapping-independent SMG6-mediated
endonucleolytic cleavage of the substrate RNA [100].
Conversely, this observation does not rule out the possi-
bility that, under physiological conditions, NMD may
occur to some extent in P-bodies, in keeping with the
reported localisation of several NMD factors and a NMD
reporter transcript to P-bodies in over-expression condi-
tions [97, 105, 162].
An extensive array of phenotypes are observed
upon inactivation of NMD effectors
While the mechanistic details of NMD are being gradually
unravelled, the physiological role of NMD still remains
largely unknown. The phenotypes observed upon inacti-
vation of NMD effectors vary considerably amongst
different organisms. NMD mutants in S. cerevisiae only
show a partial impairment in respiratory growth which is
enhanced at low temperatures [48], whereas C. elegans
mutants have defects in the male bursa and the hermaph-
rodite vulva [51, 52]. In contrast, UPF1 and UPF2 are
essential for the viability of D. melanogaster larvae [170],
and depletion of NMD factors impairs proliferation of
Drosophila embryo-derived cells (S2 cells) [19]. Likewise
in zebrafish, UPF1, UPF2, SMG5 and SMG6 were shown
to be essential for embryonic development and survival
[171]. In mice, knockout of UPF1 is embryonic lethal and
isolated blastocysts undergo apoptosis after only a few days
in culture [172]. Likewise, no UPF2 knockout mouse
embryos could be detected at day 9.5 post coitus, and
conditional knockouts of UPF2 in hematopoietic precursors
led to the complete extinction of hematopoietic stem and
progenitor cells [6]. Similarly, in Arabidopsis thaliana,
UPF1 is necessary for seedling growth [173].
Collectively, the severity of the phenotype resulting
from inactivation of the various NMD factors correlates
with the overall complexity of the organism and its extent
of alternative splicing. This allows for the speculation that
the accumulation of aberrantly spliced mRNAs and the
resulting production of detrimental C-terminally truncated
proteins may be the cause of the observed phenotypes. On
the other hand, it may be that NMD regulates the expres-
sion of an essential protein in mice and flies but not in yeast
and worms. Moreover, several of the proteins characterised
as NMD factors have also been reported to function in
cellular processes seemingly unrelated to NMD, and it is
therefore equally plausible that the observed phenotypes
are the consequence of disrupting these NMD-independent
mechanisms.
In selenium-deprived cells, NMD reduces
the selenoprotein encoding mRNA
Selenium (Se) is an essential micronutrient that is linked to
many aspects of human health. A unique class of proteins
called selenoproteins, most of which are involved in pro-
tecting the cell from oxidative stress, incorporate
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selenocysteine (Sec or U) at in-frame UGA codons in
archaea, prokaryotes and eukaryotes. Unlike the other
amino acids, Sec is made on its transfer RNA (tRNA) and
selenocysteyl-tRNA[ser]sec is delivered to the A-site of the
ribosome by a specific elongation factor called EFsec [174].
The fact that the UGA codon specifies Sec incorporation
rather than translation termination is chiefly due to the
presence of specific secondary structures in selenoprotein-
encoding mRNAs termed selenocysteine insertion (SECIS)
elements, and the trans-acting factors that associate with
these SECIS elements. In eukaryotes, the SECIS element is
located in the 30 UTR (reviewed in [175]). A protein called
SECIS binding protein 2 (SBP2) binds to SECIS elements
and to the large ribosomal subunit and recruits the eEFsec-
selenocysteyl-tRNA[ser]sec complex to the ribosome,
ensuring efficient Sec incorporation in vivo and in vitro
[175, 176]. Moreover, SBP2 can actually suppress the
termination promoting function of eRF1 [177].
The efficiency of Sec incorporation varies depending on
the nature of the SECIS element, the position of the UGA
in the ORF [178] and the nucleotides surrounding it [177,
179], as well as the intracellular selenium concentration
[22]. It was observed that Se deficiency decreases the
abundance of mRNAs encoding the selenoprotein, gluta-
thione peroxidase 1, and that this is possibly mediated by
the NMD pathway [22]. The mRNA coding for phospho-
lipid hydroperoxide glutathione peroxidase (PHGPx) was
also reported to be an NMD target in NIH3T3 fibroblasts or
H35 hepatocytes under Se-deprived conditions [180], but
no corresponding change in PHGPx mRNA abundance in
the liver or testis of Se-deficient rats was observed [181]. It
was suggested that a mechanism absent in mouse NIH3T3
fibroblasts and rat H35 hepatocytes masks the NMD of
PHGPx mRNA in the rat liver and testis [180]. Given the
importance of selenoproteins to the viability of the animal
and their specialised functions, the fact that these proteins
are highly conserved and ancient, the complex cis-acting
elements and trans-acting factors that ensure that the UGA
codon is not read as a stop codon and their intricate hier-
archy of expression which matches the Se intake, it may be
that, under physiological conditions, NMD in combination
with additional, presently unknown processes acts to reg-
ulate the stability of selenoprotein encoding mRNAs.
The multiple personalities of the NMD factors UPF1,
SMG1 and SMG6
Staufen-1-mediated mRNA decay (SMD) and NMD
are competitive pathways
The double-stranded RNA binding protein Staufen was
originally identified as a maternal factor required for the
correct formation of the anterioposterior axis in the
D. melanogaster embryo [182, 183]. Staufen is principally
known to be involved in the transport of mRNAs to ulti-
mately achieve their localised translation [184, 185], in
mice [186] and in humans [186, 187]. Mammalian Staufen
protein has four double-strand RNA binding domains
(dsRBDs) and contains a putative microtubule-binding
domain of microtubule-associated protein 1B in its C-ter-
minus that is not present in the Staufen protein of
D. melanogaster or C. elegans [187].
In addition to Staufen’s previously characterised func-
tions, mammalian Staufen was found to play a role in
mRNA decay [188]. Yeast two-hybrid analysis revealed
that Staufen-1 (STAU1) interacts with UPF1, and this
interaction was confirmed by GST pull-downs and far
western blotting (Table 3). Tethering of STAU1 to a
reporter mRNA can induce UPF1-dependent and transla-
tion-dependent mRNA degradation called SMD (for
STAU1-mediated mRNA decay) [188]. Natural targets of
SMD are expected to bind STAU1 downstream of the
translation termination codon and, upon depletion of either
STAU1 or UPF1, the mRNA should be stabilised. In HeLa
cells depleted for STAU1, approximately 1% of the tran-
scriptome was more than twofold up-regulated whilst
approximately 1% was more than twofold down-regulated,
inferring that STAU1 potentially acts to regulate a multi-
tude of functionally unrelated physiological transcripts and
can influence many metabolic pathways [189].
In addition to STAU1, there is a second Staufen protein
called STAU2 that is encoded by a different gene and
shares 51% amino acid identity with STAU1 [190]. Con-
sidering the high sequence similarity between STAU1 and
STAU2 and also the evidence that STAU2 co-immuno-
precipitates with mRNA from human cells [190, 191], a
genome-wide approach was undertaken to examine if
STAU1 and STAU2 can bind to and regulate a similar
collection of mRNAs. Distinct but overlapping subsets of
cellular mRNAs were found to associate with STAU1 and
STAU2 containing RNP complexes [190]. To further elu-
cidate the involvement of the Staufen proteins in
mammalian RNA metabolism, the structure of the STAU1
and STAU2 binding sites and their position relative to the
translation start and stop codons were examined. The
position of the STAU1 binding site is critical as it deter-
mines whether the mRNA is targeted for enhanced
translation [192] or if it is to be degraded by SMD [188]. It
appears that SMD is a mechanism that depends on trans-
lation and is elicited when STAU1 binds to its hairpin
binding site approximately 25–30 nucleotides downstream
from the translation termination codon. Further analysis
has indicated that the STAU1 binding site requires more
elaborate secondary structure than a single hairpin element
[189]. STAU1 is thought to recruit UPF1 to the 30 UTR via
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direct interaction [188] and, therefore, SMD may be trig-
gered by UPF1 interacting with the eRFs at the translation
termination codon analogous to NMD. With this in mind, it
will be insightful to determine if SMD also involves the
UPF1 binding endonuclease SMG6, when it elicits degra-
dation of its target transcripts. Interestingly, the STAU1
and UPF2-binding sites within UPF1 have recently been
shown to overlap, rendering STAU1 and UPF2 binding to
UPF1 mutually exclusive [193]. During the differentiation
of C2C12 myoblasts to myotubes, NMD and SMD path-
ways appear to be in competition: SMD activity increases
while the activity of the UPF2-dependent NMD pathway
decreases [193]. In support of the physiological importance
of this competition, SMD targets PAX3 mRNA whose
Table 3 Summary of additional NMD independent functions for UPF1, SMG1 and SMG6 in different cellular pathways
Factor Reported roles Notes of interest References
UPF1 Staufen-mediated decay pathway: STAU1
binds the 3’ UTR and recruits UPF1 to
elicit decay of the mRNA
NMD and SMD are competitive pathways,
UPF1 binds either UPF2 or STAU1 but not
to both simultaneously
[188, 189, 193]
DNA replication, repair and stability
pathways: UPF1 contributes to the
completion of DNA replication and
proper cell cycle progression
UPF1 depletion results in an early S-phase
arrest. UPF1 associates with chromatin in a
cell cycle regulated manner and when ATR
is depleted, chromatin loading of UPF1 is
impaired. c-irradiation increases UPF1
chromatin association. UPF1
co-immunoprecipitates with p66 subunit
and p125 subunits of DNA polymerase d
[103, 104, 207, 208]
Replication dependent histone mRNA
metabolism: UPF1 is important for
histone mRNA degradation
UPF1 depletion stabilises histone mRNA
after HU treatment and at the end of
S-phase. Immunoprecipitation showed that
UPF1 interacts with SLBP/HBP
[214]
HIV-1 metabolism: possibly UPF1
stabilises HIV-1 RNA in infected cells
UPF1 is a component of the HIV-1 RNP and
its function requires its ATPase activity. Its
recruitment may be mediated by STAU1.
over-expression of UPF1 results in up-
regulation of HIV-1 expression at the RNA
and protein level
[194]
Telomere metabolism: possibly UPF1
facilitates TERRA release from
telomeres
Detected in telomeric chromatin fractions.
Depletion of UPF1 increases TERRA at
telomeres and leads to telomere damage
[103, 104, 202, 203]
SMG1 Protection of genomic stability: SMG1
initiates cellular stress responses when
genome integrity, mRNA translation or
nutrient availability is compromised
SMG1 is activated by DNA damage and
stimulated by UV or c-radiation. Depletion
of SMG1 results in DNA damage and
increased sensitivity to radiation.
Phosphorylates p53 in vitro and upon
c-radiation in vivo. Along with ATM,
SMG1 can phosphorylate UPF1 in response
to dsDNA breaks caused by c-radiation.
SMG1 is important for oxidative stress
protection in C. elegans and protects
against TNF-a induced apoptosis in human
cells. SMG1 along with ATM can modulate
p21 levels to inhibit cell division, induce
DNA repair or block apoptosis
[106, 222, 224]
Telomere metabolism: possibly SMG1
facilitates TERRA release from
telomeres
Detected in telomeric chromatin fractions.
Depletion of SMG1 increases TERRA
signals and leads to telomere damage
[103, 104, 202, 203]
SMG6 Telomere metabolism: possibly SMG6
facilitates TERRA release from
telomeres
Detected in telomeric chromatin fractions.
Physically interacts with telomerase.
Depletion of SMG6 increases TERRA
signals and leads to telomere damage.
Over-expression results in end-to-end
chromosome fusions and altered telomere
lengths
[103, 104, 202–204]
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decay promotes myogenesis, while the mRNA encoding
for myogenin, a protein required for myogenesis, is an
NMD target [193].
STAU1 and UPF1 are both involved in HIV-1
metabolism
UPF1 and STAU1 were also reported to function together
in HIV-1 RNA metabolism [194–196] (Table 3). STAU1
was shown to associate with HIV-1 genomic RNA and two
to five STAU1 proteins are incorporated per HIV-1 virion
[197]. STAU1 over-expression can increase the abundance
of HIV-1 genomic RNA and of STAU1 protein packaged
into the virion [196]. RNAi-mediated depletion of STAU1
resulted in a substantial decrease of viral infectivity [195].
Moreover, STAU1 was shown in an RNA-dependent
manner to directly interact with the nucleocapsid domain of
the pr55Gag, a key mediator of HIV-1 genomic RNA en-
capsidation [195]. Therefore, the HIV-1 RNP contains the
major structural protein pr55Gag, viral genomic RNA and
the host protein STAU1, and it has been proposed that
STAU1 together with pr55Gag plays an important role in
viral assembly, genomic RNA encapsidation and the gen-
eration of infectious viral particles [195].
Recently, UPF1 was also identified as a component of
the HIV-1 RNP [194]. The presence of UPF1 with the
HIV-1 RNP is most likely mediated by STAU1 and it does
not require any interactions between UPF2 and UPF3.
Knockdown of UPF1 led to a large reduction in steady-
state HIV-1 RNA and pr55Gag protein levels, and over-
expression of UPF1 resulted in up-regulation of HIV-1
expression at the level of both RNA and protein. The
effects of UPF1 on HIV-1 RNA stability were dependent
on its ATPase activity and required ongoing translation
[194]. It was suggested that targeting of UPF1 function
might represent a suitable approach to arrest HIV-1 late in
the replication cycle [194]. Further work will shed light on
how UPF1 is recruited to the HIV-1 RNP, its exact role and
also if UPF1 function is utilised by other retroviruses.
NMD factors function at telomeres
Telomeres are the heterochromatic structures located at the
termini of linear chromosomes. They compensate for
incomplete semi-conservative DNA replication and also
protect the chromosomal ends against recombination with
each other and with double-strand breaks (DSBs) inside the
chromosomes. While repetitive sequences cover an average
of 350 base pairs in yeast telomeres, human telomeres
exceed several kilobases composed of TTAGGG repeats
[198, 199].
The first connection between NMD factors and telomere
function was reported when it was discovered that
mutations of Upf1p, Upf2p and Upf3p in yeast led to
telomere shortening and de-repression of silenced telo-
meric loci [200, 201]. Consistent with the idea that NMD
affects the expression of genes important for telomere
function, it was found that NMD mutant strains had
increased levels of mRNAs encoding the telomerase cata-
lytic subunit (Est2p), regulators of telomerase (Est1p,
Est3p, Stn1p, Ten1p) and proteins implicated in regulation
of telomeric chromatin structure (Sas2p, Orc5p) [200].
However, the picture became more complicated when
a bioinformatics search for human homologues of the
S. cerevisiae ever shorter telomeres 1 (Est1) gene identified
the same three proteins that were independently identified
as human orthologues of the C. elegans NMD factors
SMG5 (= EST1B), SMG6 (= EST1A), and SMG7
(= EST1C) [202, 203]. Moreover, EST1A/SMG6 and
EST1B/SMG5 were found to associate with telomerase
activity in human cell extracts and over-expression of
EST1A/SMG6 led to end-to-end chromosome fusions and
altered telomere lengths [202, 203] (Table 3). EST1A/
SMG6 interacts with telomerase by binding to the telo-
merase RNA with high affinity but low specificity, and also
by making protein–protein contacts with telomerase
reverse transcriptase (TERT) [204].
For a long time, telomeres were believed to be trans-
criptionally inactive. However, recently, a set of pol II
transcripts called telomeric repeat-containing RNA
(TERRA), also known as TelRNA, have been discovered in
human [104, 205] and yeast cells [206] (reviewed in [207]).
Fascinatingly, enrichment of NMD factors was detected in
telomeric chromatin fractions, and the depletion of UPF1,
SMG1 and EST1A/SMG6 (and to a lesser extent UPF2 and
EST1C/SMG7) increased TERRA signals and triggered
telomere damage, including complete telomere loss [103,
104]. Despite the presence of one UAG stop codon in each
telomeric repeat sequence, it seems that the role of the
NMD factors is most likely not to stimulate TERRA deg-
radation but rather to reduce its association with telomeres
[104]. If the increased level of TERRA at telomeres is
the cause of the telomere de-protection observed in
NMD-deficient cells, this would suggest that TERRA is
unfavourable for telomere stability. On the other hand, if
NMD-depletion triggers telomere damage independently of
an effect on TERRA, the increased association of TERRA
with telomeres could be stimulated by the cell in an attempt
to strengthen telomere protection. Similarly, the increased
levels of TERRA observed with thermal shock may help to
protect telomeres against stress-mediated damage [205].
TERRA might also be involved in the regulation of telo-
merase activity. EST1A/SMG6 physically interacts with
telomerase [204] and, in vitro, TERRA probably inhibits
telomerase by RNA duplex formation in the template
region of the telomerase RNA component (TERC) [205].
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The effect of TERRA on telomerase remains to be tested in
vivo.
The roles of UPF1 in DNA replication and repair
Evidence from several different studies has converged in
recent years to show that UPF1 plays a significant role in
DNA and RNA maintenance pathways that are necessary
for the cell to accomplish DNA replication (Table 3).
UPF1 depletion was reported to result in an early S-phase
arrest, in which the cells could fire the start of DNA rep-
lication but were unable to complete DNA replication, and
induced an ATR-dependent DNA-damage response [103].
The cells accumulated nuclear foci comprising the S-phase
marker proliferation cell nuclear antigen (PCNA), indi-
cating that UPF1 is essential for accomplishing DNA
replication during S-phase of the cell cycle. Notably,
knocking down UPF2 caused no adverse effect to S-phase
progression, suggesting that UPF1’s function in DNA
replication is unrelated to NMD [103]. It was further
observed that hyper-phosphorylated UPF1 was associated
with chromatin and that the amount of chromatin-associ-
ated UPF1 vastly increased during S-phase and also upon
c-irradiation [103]. When ATR was depleted, chromatin
loading of UPF1 was impaired, whereas NMD was not
affected under such conditions [103]. This implies that,
either during DNA replication and/or a DNA repair
response, ATR phosphorylates UPF1 leading to its asso-
ciation with chromatin, or alternatively that UPF1 is
present on the chromatin during replication and becomes
phosphorylated by ATR in response to DNA damage.
Evidence for the involvement of UPF1 in DNA replication
and repair is compounded further by the finding that UPF1
co-immunoprecipitates with the p66 subunit and p125
catalytic subunit of the replicative DNA polymerase d. In
contrast, UPF2 was not able to co-immunoprecipitate with
p125 DNA polymerase d [103, 208]. The function of UPF1
in DNA replication and cell cycle progression becomes
even more intricate by evidence showing that UPF1 is
involved in the degradation of replication dependent his-
tone transcripts upon DNA replication inhibition and at the
end of S-phase [209].
UPF1 acts in the degradation of replication-dependent
histone mRNAs
The replication-dependent histone genes provide the large
amount of histone proteins (108 molecules of each core
histone protein) required for genome duplication [210].
Histone proteins are produced during S-phase of the cell
cycle and their expression is co-ordinately regulated and
finely balanced with DNA replication. Three major pro-
cesses, transcription, mRNA 30 end processing and mRNA
stability control, contribute to the complex regulation
of histone gene expression during S-phase [211]. This
combination of transcriptional and post-transcriptional
mechanisms acts to regulate the 35-fold increase of histone
mRNA levels as cells progress from G1- into S-phase and
ensures that the mRNA abundance returns to baseline
levels as the cells exit S-phase. The half-life of histone
mRNAs decreases from 45–60 min during S-phase to
approximately 10 min at the end of S-phase due to a reg-
ulatory mechanism that acts to rapidly eliminate histone
mRNAs from the cytoplasm when DNA synthesis is
completed or inhibited. Since histone gene transcription is
only increased three to fivefold during S-phase, the post-
transcriptional regulation accounts for the remaining five to
sixfold increase in histone mRNA levels and for their rapid
elimination when DNA replication is completed or inhib-
ited (reviewed in [211–213].
Histone production and DNA synthesis are intimately
coupled by a poorly understood mechanism involving
checkpoint kinases, such as ATR and DNA-activated pro-
tein kinase (DNA-PK) [214, 215]. Additionally, UPF1 has
also been reported to play a role in histone mRNA desta-
bilisation [214–216] (Table 3). RNAi-mediated
knockdown of UPF1 (but not of UPF2) or over-expression
of dominant-negative UPF1 mutants (K498A and R843C)
resulted in an increased histone H2A mRNA level after
inhibition of DNA synthesis by hydroxyurea (HU) treat-
ment or at the end of S-phase [214]. Furthermore, a weak
interaction between UPF1 and the histone stem-loop
binding protein (SLBP; also called hairpin binding protein,
HBP) was detected in immunoprecipitation experiments.
Recently, it has been revealed that the degradation of his-
tone mRNAs requires many of the factors involved in
degradation of polyadenylated mRNA, such as LSM1,
DCP2, XRN1 and the exosome components PM/Scl-100
(RRP6) and EXOSC4 (RRP41) [217]. Furthermore, it has
been reported that histone mRNA degradation begins with
the addition of 8–12 uridines by uridylyl transferases
(TUTases) to the 30 end of the histone mRNA [217]. The
concentration of oligouridylated histone mRNAs increased
strongly 15 min after HU treatment, and knockdown of
TUTases 1 and 3 reduced the rate of histone mRNA deg-
radation [217]. UPF1 has been proposed to be involved in
the recruitment of the TUTase 1 and 3 to the histone
mRNA [217]. Alternatively, it has also been suggested that
the RNA helicase activity of UPF1 may remodel the mRNP
complex to allow the TUTases to bind the 30 end of the
mRNA [218]. So far, there is no direct evidence for either
of these roles by UPF1, and its function in histone mRNA
metabolism remains unclear.
As mentioned, the coupling of DNA replication and
histone mRNA stability is thought to be mediated by
PIKKs acting upon downstream effectors. In addition to
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SMG1 (also called ATX), the mammalian PIKKs include
ATM, ATR, mTOR/FRAP and DNA-PK. Checkpoint
regulation in mammals is intricate and ultimately unevenly
divided between ATM and ATR [219]. ATM, ATR and
DNA-PK are activated by various forms of DNA damage.
ATR is activated by aberrant DNA structures induced by
UV light or replicational stress caused by DNA replication
inhibitors, both leading to stalling of the replication fork.
ATM is mainly activated by DSBs predominately after
exposure to ionising radiation. DNA-PK is required for
DSB repair by non-homologous end-joining (NHEJ) and
telomere maintenance. In a recent study, Kaygun and
Marzluff reported that ATR but not ATM is required for
histone mRNA degradation after inhibition of DNA repli-
cation [209]. Mu¨ller et al. reported that ATR is not
functionally limiting for the rate or extent of histone
mRNA decay induced by replication stress and cannot fully
account for the coupling between DNA replication and
histone mRNA stability. Exposure of cells to an inhibitor of
DNA-PK unveiled DNA-PK also to be involved in linking
histone mRNA abundance with DNA replication [215].
DNA-PK is activated during replication stress and the
DNA-PK pathway is enhanced when ATR signalling fails,
highlighting the complex nature of such signalling path-
ways and showing that, in vivo, the relative contribution
from each signalling pathway would be based on the nature
of the DNA lesion generating the replication stress. Since
SMG1 interacts with and phosphorylates UPF1, and
because of its resemblance to these other PIKKs with
documented roles in regulation of cell cycle and DNA
replication, it is tempting to speculate that SMG1 may also
contribute to the complex signalling involved in the cou-
pling of DNA replication and histone mRNA stability.
A role for SMG1 in safeguarding genome integrity
The human members of the PIKK family all comprise
FAT, FATC and PI3K domains. SMG1 differs from the
other PIKKs because the PI3K domain is separated from
the FATC domain by a large insert of over 1,000 amino
acids, whereas only approximately 100 amino acids sepa-
rate these two domains in the other PIKKs [61, 75, 220]. In
C. elegans SMG1, this 1,000 amino acids section does not
exist. Possibly, this portion appeared during metazoan
evolution and allows SMG1 to interact with a broader
range of upstream regulatory proteins and downstream
targets [221]. In human cells, depletion of SMG1 results in
spontaneous DNA damage and a hugely increased sensi-
tivity to ionising radiation [106] (Table 3). Exposure of
cells to UV light or ionising radiation stimulates SMG1
kinase activity. Moreover, like ATM, SMG1 is able to
phosphorylate p53 at serine 15 and expression of SMG1 is
required for optimal p53 activation after genotoxic stress.
Therefore, similar to ATM and ATR, SMG1 is central to
the regulation of the genotoxic stress response machinery
in mammalian cells. Recent reports have also implicated
SMG1 to be important in the response to oxidative stress
[222]. SMG1 has been observed to initiate p53 phosphor-
ylation during the early stages of oxidative stress, and
ATM acts to maintain the p53 phosphorylation over time.
Currently, it is not clear why the activation of SMG1
precedes that of ATM in hyperoxia conditions. Experi-
ments using cells depleted of ATM also indicated that
SMG1 and ATM act sequentially and independently of
each other to regulate the G1-checkpoint during prolonged
oxidative stress [222]. Potentially, SMG1 and ATM may
recognise and respond to different lesions that are produced
due to prolonged hyperoxia. Phosphorylated p53 activates
transcription of p21 and, interestingly, it was shown that
the destabilisation of p21 during hyperoxia could be
restored by treatment with wortmannin, implying the
involvement of PIKKs [222]. Human SMG1 and ATM also
act, independently of p53, to target p21 for degradation by
the proteasome. Hence, this dual function of SMG1 and
ATM which can regulate both the synthesis and degrada-
tion of p21, thereby finely controlling the p21 levels
necessary to inhibit cell proliferation, induce DNA repair
and block apoptosis [222].
Similarly SMG1 was also found to be important in
responding to oxidative stress in C. elegans. In a study
investigating lifespan regulation in C. elegans, SMG1 was
identified in a screen for genes that prolong lifespan in a
daf-18-dependent manner [223]. Further analysis revealed
that the SMG1 function in lifespan control requires cep-1,
the C. elegans orthologue of p53. Moreover, the role of
SMG1 in lifespan control is due to its function in oxidative
stress response. Interestingly, it was also reported that in
S. pombe, Upf1p and Upf2p are required for survival of
oxidative stress [21]. To investigate the possibility that
SMG1 may have a function in stress signalling induced by
cytokines, a wide range of agents that can induce cell death
were examined in SMG1-, ATM-, ATR-, UPF1- or UPF2-
depleted cells [224]. Only depletion of SMG1, but not of
the other factors, substantially increased the rate and the
extent of apoptotic cell death mediated by tumour necrosis
factor-alpha (TNF-a) [224]. SMG1, like other PIKKs,
functions to initiate cellular stress responses when genome
integrity, mRNA translation or nutrient availability is
compromised, and the role of SMG1 in NMD represents
simply just one of its many roles.
Conclusion and future directions
Apart from increasing our understanding of the funda-
mental molecular mechanisms that control the extent and
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accuracy of the expression of our genetic information, a
principal goal of studies on NMD is to eventually utilise
the knowledge for curing diseases and improving health. In
spite of significant advances during recent years, we are
still far from understanding the complete details regarding
how mRNAs are recognised as NMD targets, their sub-
sequent degradation and the physiological importance of
NMD factors regulating up to 10% of the transcriptome.
The unified NMD model makes many testable predic-
tions and will hopefully provide a useful framework for
future mechanistic investigations. The model emphasises
the requirement of a properly configured 30 UTR for normal
translation termination. The presence of PABP nearby a
terminating ribosome is one crucial characteristic for a
properly configured 30 UTR, but additional features are
expected to exist. Deviations from this 30 UTR configura-
tion or specific factors that prohibit the termination-
promoting interaction of PABP with the translation
termination complex signals an anomaly in the mRNA
molecule and triggers NMD. The mechanistic details of
UPF1 recruitment onto the SURF complex and its sub-
sequent assembly with the ribosome remain to be worked
out. In addition, several open questions regarding the deg-
radation pathway(s) of NMD substrates need to be
addressed. For example, does mammalian NMD really
comprise two independent ways to initiate RNA decay: an
endonucleolytic SMG6-dependent route and a decapping-
dependent exonucleolytic route?
Finally, it has come to light in recent years that several
factors which were initially identified and characterised for
their roles in the NMD pathway have highly important
functions in the cell that are independent of NMD. It is
becoming more evident that UPF1 plays many roles with
regards to the regulation of S-phase progression, consid-
ering it has been reported to be involved in replication-
dependent histone mRNA metabolism, the replication
machinery, and in conjunction with SMG6 in telomere
maintenance. Additionally, there is an increased associa-
tion of UPF1 onto chromatin during S-phase and depletion
of UPF1 leads to an early S-phase arrest. Likewise, the
recently reported functions of SMG1 also indicate this
protein to be ultimately required for genome stability. It is
more difficult to relate the function of UPF1 in SMD and in
HIV-1 RNA metabolism to its S-phase and telomere
functions. It is attractive to speculate in an evolutionary
context about when UPF1 acquired these functions in
addition to its role in NMD. Replication-dependent his-
tones in yeast are polyadenylated and do not contain SLBP/
HBP; perhaps this is why depletion of UPF1 is detrimental
to human cells but not to yeast cells. An important goal for
the future is to begin to decipher what constitutes a direct
effect and an indirect effect when the NMD factors are
depleted and genome-wide microarray profiling is
conducted. The future will also be about determining the
parameters for each of the many different roles that UPF1
carries out, for instance its cellular location, its role in cell
cycle control, where and when it is phosphorylated, whe-
ther there is a specific phosphorylation pattern directing
UPF1 to its function, its stability and where and when its
many interaction partners bind. Making sense of all the
molecular functions of UPF1 will not only be critical to
understanding the mechanism of NMD, but also to eluci-
dation of all of the other processes where UPF1 has been
found to play a role.
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